苯那普利与螺内酯合用治疗高血压性心脏病充血性心力衰竭的临床疗效

目的：对苯那普利联合螺内酯治疗高血压性心脏病充血性心力衰竭的临床治疗效果进行观察。方法选取我院2011年4月~2013年4月所接收的高血压性心脏病充血性心力衰竭患者80例作为研究对象，并将其随机分为两组，即对照组与治疗组，对照组给予苯那普利进行治疗，而治疗组采取苯那普利联合螺内酯进行治疗，对两组患者的临床治疗效果进行观察。结果通过治疗，治疗组有显效18例，有效20例，总有效率为95.0%，对照组有显效15例，有效19例，总有效率为85.0%，两组比较，差异有统计学意义（P＜0.05）；而在步行6min运动耐量与LVEF上，治疗组明显优于对照组，差异有统计学意义（P＜0.05）。结论对高血压性心脏病充血性心力衰竭患者采取苯那普利联合螺内酯予以治疗，能够有效改善患者的心功能，且治疗效果显著，值得大力推广。

Observation of the clinical effect of benazepril combined with spironolactone in the treatment of hypertensive heart disease complicated with congestive heart failure

Objective To observe the clinical effect of benazepril combined with spironolactone in the treatment of hypertensive heart disease complicated with congestive heart failure. Methods 80 patients with hypertensive heart disease complicated with congestive heart failure who were admitted to our hospital from April 2011 to April 2013 were selected as research subjects. They were randomly divided into two groups, a control group and a treatment group. The control group received benazepril, and the treatment group received benazepril combined with spironolactone. Clinical effects in the two groups were observed. Results After the treatment, 18 patients in the treatment group were significantly effective and 20 patients were effective, with the total effective rate of 95.0%. 15 patients in the control group were significantly effective and 19 patients were effective, with the total effective of 85.0%. The differences between the two groups were statistically significant（P 〈 0.05）; exercise tolerance of a 6-min walk and LVEF in the treatment group were significantly better than those in the control group, and the differences were statistically significant（P 〈 0.05）. Conclusion Benazepril combined with spironolactone in the treatment of hypertensive heart disease complicated with congestive heart failure helps effectively improve patients＆#39; heart functions and has a significant curative effect, which is worthy of widespread promotion.